Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy D Heidel

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2014
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNAJonathan E Zuckerman, Ismael Gritli, Anthony Tolcher, et al.
Nucleic Acids Research|July 29, 2005
Functional polarity is introduced by Dicer processing of short substrate RNAsScott D Rose, Dong-Ho Kim, Mohammed Amarzguioui, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2007
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAJeremy D Heidel, Zhongping Yu, Joanna Yi-Ching Liu, et al.
Nature|March 23, 2010
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesMark E Davis, Jonathan E Zuckerman, Chung Hang J Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivoJeremy D Heidel, Joanna Yi-Ching Liu, Yun Yen, et al.
Nature Medicine|October 6, 2009
Development of universal antidotes to control aptamer activitySabah Oney, Ruby T S Lam, Kristin M Bompiani, et al.
Shock (Augusta, Ga.)|November 27, 2008
Targeted delivery of siRNA to cell death proteins in sepsisPavan Brahmamdam, Eizo Watanabe, Jacqueline Unsinger, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2014
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNAJonathan E Zuckerman, Ismael Gritli, Anthony Tolcher, et al.
Nucleic Acids Research|July 29, 2005
Functional polarity is introduced by Dicer processing of short substrate RNAsScott D Rose, Dong-Ho Kim, Mohammed Amarzguioui, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2007
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAJeremy D Heidel, Zhongping Yu, Joanna Yi-Ching Liu, et al.
Nature|March 23, 2010
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesMark E Davis, Jonathan E Zuckerman, Chung Hang J Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivoJeremy D Heidel, Joanna Yi-Ching Liu, Yun Yen, et al.
Nature Medicine|October 6, 2009
Development of universal antidotes to control aptamer activitySabah Oney, Ruby T S Lam, Kristin M Bompiani, et al.
Shock (Augusta, Ga.)|November 27, 2008
Targeted delivery of siRNA to cell death proteins in sepsisPavan Brahmamdam, Eizo Watanabe, Jacqueline Unsinger, et al.
Pageof 2